CD44在垂体腺瘤中的表达及其临床意义

目的:研究垂体腺瘤(pituitaryadenoma)中细胞粘附分子(CD44)的表达,探讨CD44对垂体腺瘤诊断及预后意义。方法:用免疫组化(SP)的方法检测 20例侵袭性垂体腺瘤, 18例非侵袭性垂体腺瘤, 6例复发性垂体腺瘤中CD44s、CD44v5蛋白的表达。结果: 20例侵袭性垂体腺瘤中CD44s、CD44v5阳性率分别为 75%、35%, 18例非侵袭性垂体腺瘤中CD44s、CD44v5阳性率分别为 27. 8%、22. 2%, 6例复发性垂体腺瘤中CD44s、CD44v5阳性率分别为 100%、66. 7%。CD44s在侵袭性垂体腺瘤及复发性垂体腺瘤中的阳性表达率均明显高于非侵袭性垂体腺瘤,其差异具有显著性 (P<0. 01),CD44v5在侵袭性垂体腺瘤中和非侵袭性垂体腺瘤中的表达率均较低,无显著性差异(P>0. 05),但在复发性垂体腺瘤中有较高表达率。结论:CD44s在侵袭性垂体腺瘤中呈高表达,与垂体腺瘤的侵袭性生长有关,在垂体腺瘤的侵袭性生长过程中起重要作用,有可能作为侵袭性垂体腺瘤的一个诊断指标。CD44v5在垂体腺瘤中的表达较低,与垂体腺瘤生长方式无关。复发性垂体腺瘤中CD44s、CD44v5的高表达表明其预后较差。

Expression of CD44 in pituitary adenoma and its clinical significance

Objective To study the expression of CD44 in pituitary adenoma and investigate its diagnostic and prognostic significance of CD44 in pituitary adenoma.Methods Expression of CD44s and CD44v 5 were detected in human surgically resected samples of pituitary adenoma(20 invasive、18 non-invasive and 6 recurrent pituitary adenoma), using S-P immunohistchemical staining method. Result The positive staining rates of CD44s and CD44v 5 were 75%、35% respectively in 20 invasive pituitary adenomas.The positive staining rates of CD44s and CD44v 5 were 27.8%、22.2% respectively in 18 non-invasive pituitary adenomas.The positive staining rates of CD44s and CD44v 5 100%、66.7% in 6 recurrent pituitary adenoma respectively. The positive staining rate of CD44s are significantly higher in invasive and recurrent pituitary adenoma than in non-invasive pituitary adenoma(P<0.01).Low levels of CD44v 5 expression were observed in both invasive and non-invasive pituitary tumor and there was no significant difference. Conclusion The results suggest that higher expressions of CD44s in invasive pituitary adenoma were correlated with pituitary adenoma invasiveness,CD44s may play an important role in invasive pituitary adenoma and can be used for diagnosis of invasive pituitary. Lower expression of CD44v 5 in pituitary adenoma was not related with invasiveness of pituitary adenoma.While the higher expression of CD44s and CD44v 5 show the poor prognosis of recurrent pituitary adenoma.